Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 6305.56 Crore) operating in Pharmaceuticals sector.
By ETMarkets.com | Updated:
ThinkStock Photos
Promoters held 29.7 per cent stake in the company as of June 30, 2020, while FIIs held 26.8 per cent, DIIs 19.4 per cent and public and others 24.1 per cent.
ICICI Securities has given buy rating to Strides Pharma with a target price of Rs 773. The share price moved up by 2.90 per cent from its previous close of Rs 681.60. The stock’s last traded price is Rs 701.40 .
Strides Pharma Science Ltd., incorporated in the year 1990, is a Mid Cap company (having a market cap of Rs 6305.56 Crore) operating in Pharmaceuticals sector.
Strides Pharma Science Ltd. key Products/Revenue Segments include Pharmaceuticals which contributed Rs 1356.43 Crore to Sales Value (88.22 % of Total Sales), Other Operating Revenue which contributed Rs 97.53 Crore to Sales Value (6.34 % of Total Sales), Export Incentives which contributed Rs 30.40 Crore to Sales Value (1.97 % of Total Sales), Sale of services which contributed Rs 29.58 Crore to Sales Value (1.92 % of Total Sales) and Royalty Income which contributed Rs 23.49 Crore to Sales Value (1.52 % of Total Sales)for the year ending 31-Mar-2019.
Financials For the quarter ended 30-06-2020, the company reported a Consolidated sales of Rs 781.80 Crore, up 26.37 % from last quarter Sales of Rs 618.64 Crore and up 14.00 % from last year same quarter Sales of Rs 685.80 Crore. The Company reported net profit after tax of Rs 122.80 Crore in latest quarter. Promoter/FII Holdings Promoters held 29.7 per cent stake in the company as of June 30, 2020, while FIIs held 26.8 per cent, DIIs 19.4 per cent and public and others 24.1 per cent.
